Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 18/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9964378 | 1.00 | CD274 (0.35) | CD274PDCD1FFAR1 | |
| SCHEMBL9964380 | 0.97 | CD274 (0.36) | CD274PDCD1FFAR1 | |
| SCHEMBL9964360 | 0.90 | CD274 (0.33) | CD274PDCD1FFAR1 | |
| SCHEMBL9964357 | 0.90 | CD274 (0.36) | CD274PDCD1FFAR1 | |
| SCHEMBL9964392 | 0.89 | CD274 (0.33) | CD274PDCD1FFAR1 | |
| SCHEMBL9934293 | 0.89 | CD274 (0.33) | CD274PDCD1FFAR1 | |
| SCHEMBL9964389 | 0.89 | CD274 (0.33) | CD274PDCD1FFAR1 | |
| SCHEMBL9966701 | 0.88 | CD274 (0.43) | CD274PDCD1 | |
| SCHEMBL9964386 | 0.88 | CD274 (0.36) | CD274PDCD1FFAR1 | |
| SCHEMBL9964384 | 0.88 | CD274 (0.36) | CD274PDCD1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024155618-A1 | COMPOSITIONS AND METHODS FOR TREATING WEIGHT GAIN AND/OR DISORDERS ASSOCIATED WITH ABNORMAL DE NOVO LIPOGENESIS, AND FAT ACCUMULATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20220411490-A1 | METHOD TO IDENTIFY COMPOUNDS USEFUL TO TREAT DYSREGULATED LIPOGENESIS, DIABETES, AND RELATED DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-12-29 | — | — | US | disclosed |
| EP-4081535-A1 | STAPLED LACTAM CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | Merck Sharp & Dohme LLC (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-4081243-A1 | STAPLED TRIAZOLE CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | Merck Sharp & Dohme LLC (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-4081244-A1 | STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | Merck Sharp & Dohme LLC (US) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411490-A1 | METHOD TO IDENTIFY COMPOUNDS USEFUL TO TREAT DYSREGULATED LIPOGENESIS, DIABETES, AND RELATED DISORDERS | FABP4, LIPC, CNR2 | CD274 4767/4885PDCD1 4510/4885FFAR1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.